Trial Profile

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir (Primary) ; SH-229 (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Nanjing Sanhome Pharmaceutical

Most Recent Events

19 Oct 2023 Status changed from active, no longer recruiting to completed according to results published in the Infectious Diseases and Therapy.
19 Oct 2023 Results published in the Infectious Diseases and Therapy
01 Jun 2022 Results published in the Journal of Viral Hepatitis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com